Conference call scheduled for 4:30 p.m. ET today

ANN ARBOR, MI / ACCESSWIRE / November 13, 2019 / ENDRA Life Sciences Inc. ('ENDRA') (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), today provided a business update and reported third quarter 2019 financial results.

'ENDRA has made important clinical and operational progress this quarter as we move towards commercialization during 2020,' said Francois Michelon, chairman and chief executive officer. 'Completion of part two of the feasibility study at Robarts Research Institute represented a major milestone in the advancement of our pioneering TAEUS technology. Initial findings support our belief that TAEUS is positioned to be a practical tool for use with other biomarkers in the management of NAFLD and NASH at the point of patient care, and we are moving ahead with additional clinical study sites and regulatory filings. We also continue to engage with our key clinical audiences as we ramp up commercialization efforts heading into 2020.'

Business Highlights

• Reported top level findings from part two of the feasibility study at Robarts Research Institute.
• Showcased the pre-production TAEUS liver device[1] for the first time at the Annual 2019 AASLD Liver Meeting.
• Hosted Key Opinion Leader (KOL) event in conjunction with the Annual 2019 AASLD Liver Meeting featuring a presentation by Dr. Raza Malik, M.D., Ph.D. Director of Hepatology and Associate Chief, Division of Gastroenterology at Tufts Medical Center.
• Increased intellectual property (IP) portfolio to 60 assets defined, filed and issued.

Financial Results for Quarter Ended September 30, 2019

• Operating expenses increased to $2.6 million in the third quarter of 2019, up from $2.4 million in the third quarter of 2018. The increase in operating expenses was primarily due to expenses related to the development of our TAEUS product line, and costs associated with the pre-commercialization of TAEUS.
• Net loss in Q3 2019 totaled $3.4 million, or ($0.46) per basic and diluted share, as compared to a net loss of $2.8 million, or ($0.70) per basic and diluted share in Q3 2018.
• Cash at September 30, 2019 totaled $2.3 million, as compared to $6.5 million at December 31, 2018, with no long-term debt outstanding.

Conference Call and Webcast Access

Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide an update on recent corporate developments.

Dial-in Number
U.S./Canada Dial-in Number: 844-602-0380
International Dial-in Number: 862-298-0970

Replay Dial-in Number: 877-481-4010
Replay International Dial-in Number: 919-882-2331
Replay Passcode: 56751

A telephone replay will be available November 13, 2019 through 4:30 p.m. ET on November 27, 2019.

A live audio webcast will be available through the Events and Presentations page of the Investors section of the company's website at www.endrainc.com. A replay of the webcast will be available on the website for 90 days.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), a ground-breaking technology that mirrors some applications similar to CT or MRI, but at 50X lower cost, at the point of patient care. TAEUS is designed to work in concert with one million ultrasound systems in global use today. TAEUS is initially focused on the measurement of fat in the liver, as a means to assess and monitor NAFLD and NASH, chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures. www.endrainc.com

Forward-Looking Statements

All statements in this release that are not based on historical fact are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as 'believe,' 'expect,' 'may,' 'will,' 'should,' 'could,' 'seek,' 'intend,' 'plan,' 'goal,' 'estimate,' 'anticipate' or other comparable terms. Examples of forward-looking statements include, among others, estimates of the timing of future events and achievements, such as obtaining a CE Mark and commercializing the TAEUS device; and expectations concerning ENDRA's business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including, among others, our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; our ability to find and maintain development partners, market acceptance of our technology, the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this release speak only as of the date of this release, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

Company Contact:

David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Media & Investor Relations Contact:

MacDougall
Christi Waarich
(781) 235-3060
endra@macbiocom.com
www.macbiocom.com

[1] Regulatory disclaimer: The TAEUS device is not yet approved for sale.

ENDRA Life Sciences Inc.
Condensed Consolidated Balance Sheets

ENDRA Life Sciences Inc.
Condensed Consolidated Statements of Operations
(Unaudited)

		Three Months Ended				Three Months Ended				Nine Months Ended				Nine Months Ended
		September 30,				September 30,				September 30,				September 30,
		2019				2018				2019				2018
Revenue		$	-			$	-			$	-			$	6,174
Cost of Goods Sold			-				-				-				-
Gross Profit		$	-			$	-			$	-			$	6,174
Operating Expenses
Research and development			1,468,441				1,162,911				4,546,746				3,671,490
Sales and marketing			100,203				72,179				245,364				220,713
General and administrative			1,071,889				832,884				2,920,815				2,842,631
Impairment of inventory			-				287,541				-				287,541
Total operating expenses			2,640,533				2,355,515				7,712,925				7,022,375
Operating loss			(2,640,533	)			(2,355,515	)			(7,712,925	)			(7,016,201	)
Other Expenses
Amortization of debt discount			(728,417	)			(377,606	)			(728,417	)			(383,428	)
Other expense			(44,612	)			(25,455	)			(55,328	)			(31,022	)
Total other expenses			(773,029	)			(403,061	)			(783,745	)			(414,450	)
Loss from operations before income taxes			(3,413,562	)			(2,758,576	)			(8,496,670	)			(7,430,651	)
Provision for income taxes			-				-				-				-
Net Loss		$	Share article: Watch latest videos Subscribe and Follow Get a daily dose of Miami Mirror news through our daily email, its complimentary and keeps you fully up to date with world and business news as well. Subscribe Now News RELEASES Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Miami Mirror. More Information 92 ℉ Mostly Cloudy in Miami Business Section 5,000 English pubs have closed in last 5 years Coronavirus has had an unprecedented impact on pubs in Britain. The British Beer and Pub Association estimates that the industry ... Ban on flights to and from India extended until end of July NEW DELHI, India, July 3 (ANI): The ban on international commercial passenger flights to and from India has been extended ... Asian stocks see out week on positive note SYDNEY, Australia - Stocks in Asia extended gains on Friday as strong payrolls data out of the U.S. and a ... Axis Bank to wind down and close operations in Britain MUMBAI, Maharashtra, India - Private sector lender Axis Bank is fully winding down and closing operations of its subsidiary in ... Wall Street rallies on final trading day of week NEW YORK, New York - U.S. stock markets defied the gloom and doom over the surge in Covid-19 cases, sending ... Sonalika confirmed as No. 1 exporter of tractors in India HOSHIARPUR, Punjab, India - Not only has the company set the pace, it has reported its highest monthly sales ever. ... International Section U.S. court orders seizure of gas shipments destined for Venezuela WASHINGTON, DC - The U.S. government has filed a forfeiture complaint and warrant against four Iranian vessels travelling to Venezuela ... 45,000 U.S. National Guards members helping in fight against Covid-19 Some 120,000 members of the U.S. National Guard have responded this year to natural disasters - floods in Michigan, wildfires ... Trump projecting confidence, election still four months away WASHINGTON, DC - Amid plummeting poll numbers and mounting pressure over his handling of the pandemic, Black Lives Matter protests ... No stopping U.S. military-industrial complex On June 13, President Donald Trump told the graduating class at West Point, "We are ending the era of endless ... India's Navy repatriates 687 citizens who were stranded in Iran THOOTHUKUDI, Tamil Nadi, India - The Indian Navy Ship Jalashwa, carrying 687 stranded citizens, including two women, arrived in Tuticorin ... Black hole discovery leaves researchers looking for more black holes CANBERRA, Australia - We now know just how massive the fastest-growing black hole in the universe actually is, as well ... Movie Review War of the Worlds (2005) (4K UHD)